SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Ayala Pharmaceuticals, Inc. (ADXS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 26/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ADXS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio279.45
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-7.99
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$-14.49 |
$1M |
$-16.53M |
-1652.5% |
| 2015 |
$-25.17 |
$0.00 |
$-47.03M |
- |
| 2016 |
$-31.17 |
$3.99M |
$-73.56M |
-1841.3% |
| 2017 |
$-34.58 |
$12.03M |
$-93.44M |
-776.6% |
| 2018 |
$-19.37 |
$6.06M |
$-66.52M |
-1097.1% |
| 2019 |
$-93.60 |
$2.33M |
$-17.79M |
-762.3% |
| 2020 |
$-34.71 |
$253K |
$-26.47M |
-10462.1% |
| 2021 |
$-11.07 |
$3.24M |
$-17.86M |
-551.3% |
| 2022 |
$-7.90 |
$250K |
$-14.36M |
-5743.6% |
| 2023 |
$-7.99 |
$13K |
$-48.07M |
-369784.6% |
